The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer ...
Dec 6, 2020
0
5
The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive (ER+) breast cancer—the most common form of breast cancer in Australia—according to preclinical studies led by Walter ...
May 7, 2020
0
260
Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia (CLL), have been shown to be effective when given together for high-risk and older patients with the disease, according to a study ...
May 29, 2019
0
14
(HealthDay)—Venetoclax (VENCLEXTA) has been approved to treat adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, the U.S. Food and Drug Administration announced yesterday.
May 17, 2019
0
1
With more targeted therapies being approved each year for cancer, the development of drug resistance to these agents is a growing concern. It has often been assumed that drug resistance is due to the presence or development ...
May 15, 2019
0
14
Researchers in Finland have discovered a drug combination that collaborates with the cancer cell oncoprotein MYC, which, in large quantities, causes self-destruction of the cancer cells. When this combination is enhanced ...
Feb 6, 2019
0
6
Older patients with acute myeloid leukemia (AML) often aren't healthy enough to receive intensive chemotherapy, and gentler treatments aren't very effective in treating this aggressive blood cancer.
Nov 29, 2018
0
4
Until now, there has been no adequate treatment available for the rare and highly aggressive malignant blood disease T-PLL leukaemia. By screening blood samples from patients with haematological diseases, a team of doctors ...
Oct 24, 2017
0
19
Patients whose acute myelogenous leukemia (AML) had relapsed or was resistant to chemotherapy and those who were deemed unable to tolerate chemotherapy experienced responses to the selective BCL-2 inhibitor venetoclax (Venclexta), ...
Aug 15, 2016
0
4
